0000000000736736
AUTHOR
A. Gonschior
Net-charge fluctuations in Pb-Pb collisions at sqrt[sNN]=2.76TeV.
We report the first measurement of the net-charge fluctuations in Pb-Pb collisions at $\sqrt{s_{NN}}$ = 2.76 TeV, measured with the ALICE detector at the CERN Large Hadron Collider. The dynamical fluctuations per unit entropy are observed to decrease when going from peripheral to central collisions. An additional reduction in the amount of fluctuations is seen in comparison to the results from lower energies. We examine the dependence of fluctuations on the pseudo-rapidity interval, which may account for the dilution of fluctuations during the evolution of the system. We find that the ALICE data points are between the theoretically predicted values for a hadron gas and a Quark-Gluon Plasma.…
Anisotropic flow of charged hadrons, pions and (anti-)protons measured at high transverse momentum in Pb–Pb collisions at sNN=2.76 TeV
The elliptic, v(2), triangular, v(3), and quadrangular, v(4), azimuthal anisotropic flow coefficients are measured for unidentified charged particles, pions, and (anti-)protons in Pb-Pb collisions at root S-NN = 2.76 TeV with the ALICE detector at the Large Hadron Collider. Results obtained with the event plane and four-particle cumulant methods are reported for the pseudo-rapidity range vertical bar eta vertical bar 8 GeV/c. The small p(T) dependence of the difference between elliptic flow results obtained from the event plane and four-particle cumulant methods suggests a common origin of flow fluctuations up to p(T) = 8 GeV/c. The magnitude of the (anti-)proton elliptic and triangular flo…
Deterioration in quality of life (QOL) in patients with malignant ascites : Results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone
Background: Malignant ascites (MA) is associated with poor prognosis and limited palliative therapeutic options. Therefore, quality of life (QoL) assessment is of particular importance to demonstrate new treatment value. Following the demonstration of the superiority of catumaxomab and paracentesis over paracentesis on puncture-free survival, this analysis aimed at comparing deterioration in QoL between both the treatment options. Patients and methods: In a randomised, multicentre, phase II/III study of patients with MA due to epithelial cell adhesion molecule (EpCAM) positive cancer, the QoL was evaluated using the European Organisation for Research and Treatment of Cancer Quality of Life …